Literature DB >> 34168239

GREB1L overexpression correlates with prognosis and immune cell infiltration in lung adenocarcinoma.

Yilin Yu1, Zhiping Wang1, Qunhao Zheng1, Jiancheng Li2.   

Abstract

GREB1L is a protein-coding gene that is an important paralog of GREB1. However, its effects in lung adenocarcinoma (LUAD) have not been determined. Thus, we evaluated the prognostic value of GREB1L in LUAD using bioinformatics approaches. In particular, we evaluated the relationship between GREB1L and LUAD using a wide range of databases and analysis tools, including TCGA, GEO, HPA, TIMER, cBioPortal, and MethSurv. Compared with its expression in normal lung tissues, GREB1L expression was significantly increased in LUAD tissues. A univariate Cox analysis showed that high GREB1L expression levels were correlated with a poor OS in LUAD. Additionally, GREB1L expression was independently associated with OS through a multivariate Cox analysis. GSEA analysis revealed enrichment in cell cycle, immune regulation, and methylation. Moreover, high GREB1L expression was associated with poor survival. We also found that the methylation and genetic alteration level was associated with prognosis in patients with LUAD. Finally, an analysis of immune infiltration showed that GREB1L is correlated with immune cell infiltration, PD-1, and PD-L1. In summary, these results indicate that GREB1L is a potential molecular marker for poor prognosis in LUAD and provide additional insight for the development of therapies and prognostic markers.

Entities:  

Year:  2021        PMID: 34168239     DOI: 10.1038/s41598-021-92695-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  26 in total

1.  De novo variants in GREB1L are associated with non-syndromic inner ear malformations and deafness.

Authors:  Isabelle Schrauwen; Elina Kari; Jacob Mattox; Lorida Llaci; Joanna Smeeton; Marcus Naymik; David W Raible; James A Knowles; J Gage Crump; Matthew J Huentelman; Rick A Friedman
Journal:  Hum Genet       Date:  2018-06-28       Impact factor: 4.132

2.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Authors:  Mark G Kris; Bruce E Johnson; Lynne D Berry; David J Kwiatkowski; A John Iafrate; Ignacio I Wistuba; Marileila Varella-Garcia; Wilbur A Franklin; Samuel L Aronson; Pei-Fang Su; Yu Shyr; D Ross Camidge; Lecia V Sequist; Bonnie S Glisson; Fadlo R Khuri; Edward B Garon; William Pao; Charles Rudin; Joan Schiller; Eric B Haura; Mark Socinski; Keisuke Shirai; Heidi Chen; Giuseppe Giaccone; Marc Ladanyi; Kelly Kugler; John D Minna; Paul A Bunn
Journal:  JAMA       Date:  2014-05-21       Impact factor: 56.272

3.  LncRNA TDRG1 promotes the metastasis of NSCLC cell through regulating miR-873-5p/ZEB1 axis.

Authors:  Xiufeng Hu; Yu Mu; Jiaojie Wang; Yanqiu Zhao
Journal:  J Cell Biochem       Date:  2019-11-19       Impact factor: 4.429

Review 4.  The immune contexture in human tumours: impact on clinical outcome.

Authors:  Wolf Herman Fridman; Franck Pagès; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2012-03-15       Impact factor: 60.716

Review 5.  Classification and Pathology of Lung Cancer.

Authors:  Min Zheng
Journal:  Surg Oncol Clin N Am       Date:  2016-07       Impact factor: 3.495

Review 6.  DNA Methylation in Cancer and Aging.

Authors:  Michael Klutstein; Deborah Nejman; Razi Greenfield; Howard Cedar
Journal:  Cancer Res       Date:  2016-06-02       Impact factor: 12.701

Review 7.  Cancer immune contexture and immunotherapy.

Authors:  Etienne Becht; Nicolas A Giraldo; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf Herman Fridman
Journal:  Curr Opin Immunol       Date:  2015-12-17       Impact factor: 7.486

8.  Mutations in GREB1L Cause Bilateral Kidney Agenesis in Humans and Mice.

Authors:  Lara De Tomasi; Pierre David; Camille Humbert; Flora Silbermann; Christelle Arrondel; Frédéric Tores; Stéphane Fouquet; Audrey Desgrange; Olivier Niel; Christine Bole-Feysot; Patrick Nitschké; Joëlle Roume; Marie-Pierre Cordier; Christine Pietrement; Bertrand Isidor; Philippe Khau Van Kien; Marie Gonzales; Marie-Hélène Saint-Frison; Jelena Martinovic; Robert Novo; Juliette Piard; Christelle Cabrol; Ishwar C Verma; Ratna Puri; Hubert Journel; Jacqueline Aziza; Laurent Gavard; Marie-Hélène Said-Menthon; Laurence Heidet; Sophie Saunier; Cécile Jeanpierre
Journal:  Am J Hum Genet       Date:  2017-11-02       Impact factor: 11.025

Review 9.  Epigenetic biomarkers of promoter DNA methylation in the new era of cancer treatment.

Authors:  Keishi Yamashita; Kei Hosoda; Nobuyuki Nishizawa; Hiroshi Katoh; Masahiko Watanabe
Journal:  Cancer Sci       Date:  2018-10-26       Impact factor: 6.716

10.  Genomic study of severe fetal anomalies and discovery of GREB1L mutations in renal agenesis.

Authors:  Sarah Boissel; Catherine Fallet-Bianco; David Chitayat; Valérie Kremer; Christina Nassif; Françoise Rypens; Marie-Ange Delrue; Dorothée Dal Soglio; Luc L Oligny; Natalie Patey; Elisabeth Flori; Mireille Cloutier; David Dyment; Philippe Campeau; Aspasia Karalis; Sonia Nizard; William D Fraser; François Audibert; Emmanuelle Lemyre; Guy A Rouleau; Fadi F Hamdan; Zoha Kibar; Jacques L Michaud
Journal:  Genet Med       Date:  2017-10-26       Impact factor: 8.822

View more
  3 in total

1.  Identification and Validation Prognostic Impact of MiRNA-30a-5p in Lung Adenocarcinoma.

Authors:  Xiulin Jiang; Yixiao Yuan; Lin Tang; Juan Wang; Dahang Zhang; William C Cho; Lincan Duan
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

2.  Genetic Alteration, Prognostic and Immunological Role of Acyl-CoA Synthetase Long-Chain Family Member 4 in a Pan-Cancer Analysis.

Authors:  Yongsheng Yu; Xuepu Sun; Fei Chen; Miao Liu
Journal:  Front Genet       Date:  2022-01-20       Impact factor: 4.599

Review 3.  The emerging potentials of lncRNA DRAIC in human cancers.

Authors:  Qinfan Yao; Xiuyuan Zhang; Dajin Chen
Journal:  Front Oncol       Date:  2022-08-04       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.